Strategic line 2 is called ‘Cancer Genomics’ and encompasses research activity aimed at generating new knowledge to enable the development of new therapeutic approaches to different types of cancer using systems biology methodology such as artificial intelligence.

The activity of the research groups in this strategic line makes GENyO an international benchmark in the knowledge of the molecular bases underlying the development of cancer. GENyO groups contribute to establishing the basic molecular mechanisms underlying the development of different types of cancer, identify new bio-markers useful in clinical practice and contribute to the design of new therapeutic approaches.

Research Groups

Within the line dedicated to Cancer Genomics research, we can find the following associated research groups:

Research

Publications